Prostate cancer is the second most common cancer among men globally and the fifth leading cause of cancer death in Taiwan (2023). Standard treatments often lead to drug resistance, reducing 5-year survival in castration-resistant prostate cancer (CRPC) to 30%. ITRI developed “ITRI-148,” Taiwan’s first oral PROTAC drug targeting AR/AR-V7. Designed for drug-resistant CRPC, it selectively degrades diseased proteins with low toxicity and shows superior efficacy over existing therapies.
ITRI is a world-leading applied technology research institute with more than 6,000 outstanding employees. Its mission is to drive industrial development, create economic value, and enhance social well-being through technology R&D. Founded in 1973, it pioneered in IC development and started to nurture new tech ventures and deliver its R&D results to industries. ITRI has set up and incubated companies such as TSMC, UMC, Taiwan Mask Corp., Epistar Corp., Mirle Automation Corp., and Taiwan Biomaterial Co.
Name：Chiu-Lien Hung
Phone：(03)5743961
Address：195, Sec. 4, Chung Hsing Rd., Chutung, Hsinchu, Taiwan 31040, R.O.C.
An Oral AR/AR-V7 PROTAC for the Treatment with Castration-Resistant Prostate Cancer (CRPC)
NTSR1-ADC: A Novel Therapeutics for Head and Neck Cancer
Therapeutic Humanized Anti-CD24 Monoclonal Antibody for Precision Targeted Therapy of Triple-Negative Breast Cancer
Novel cancer immunotherapeutic agent targeting tumor and tumor immune microenvironment for the treatment of triple negative breast cancer
Technology maturity：Mass production
Exhibiting purpose：Display of scientific results
Trading preferences：Negotiate by self
*Organization
*Name
*Phone
*Main Purpose
*Discuss Further
*Job Category
*Overall Rating
*Favorite Area
*Key Tech Focus
*Willing to Receive Updates?
Other Suggestions
Coming soon!